Literature DB >> 27573728

Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Joerg C Schefold1, Gerasimos Filippatos2, Gerd Hasenfuss3, Stefan D Anker4, Stephan von Haehling4.   

Abstract

Heart failure (HF) is a major health-care problem and the prognosis of affected patients is poor. HF often coexists with a number of comorbidities of which declining renal function is of particular importance. A loss of glomerular filtration rate, as in acute kidney injury (AKI) or chronic kidney disease (CKD), independently predicts mortality and accelerates the overall progression of cardiovascular disease and HF. Importantly, cardiac and renal diseases interact in a complex bidirectional and interdependent manner in both acute and chronic settings. From a pathophysiological perspective, cardiac and renal diseases share a number of common pathways, including inflammatory and direct, cellular immune-mediated mechanisms; stress-mediated and (neuro)hormonal responses; metabolic and nutritional changes including bone and mineral disorder, altered haemodynamic and acid-base or fluid status; and the development of anaemia. In an effort to better understand the important crosstalk between the two organs, classifications such as the cardio-renal syndromes were developed. This classification might lead to a more precise understanding of the complex interdependent pathophysiology of cardiac and renal diseases. In light of exceptionally high mortality associated with coexisting HF and kidney disease, this Review describes important crosstalk between the heart and kidney, with a focus on HF and kidney disease in the acute and chronic settings. Underlying molecular and cellular pathomechanisms in HF, AKI and CKD are discussed in addition to current and future therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27573728     DOI: 10.1038/nrneph.2016.113

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  192 in total

Review 1.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

Review 2.  Modification of cardiovascular risk in hemodialysis patients: an evidence-based review.

Authors:  David W Johnson; Ann-Maree Craven; Nicole Maree Isbel
Journal:  Hemodial Int       Date:  2007-01       Impact factor: 1.812

Review 3.  Clinical epidemiology of cardiovascular disease in chronic renal disease.

Authors:  R N Foley; P S Parfrey; M J Sarnak
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

Review 4.  The cardiorenal syndrome in heart failure.

Authors:  Kevin Damman; Adriaan A Voors; Gerjan Navis; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Prog Cardiovasc Dis       Date:  2011 Sep-Oct       Impact factor: 8.194

5.  Acute renal failure in critically ill patients: a multinational, multicenter study.

Authors:  Shigehiko Uchino; John A Kellum; Rinaldo Bellomo; Gordon S Doig; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Claudio Ronco
Journal:  JAMA       Date:  2005-08-17       Impact factor: 56.272

6.  Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.

Authors:  J D Harnett; R N Foley; G M Kent; P E Barre; D Murray; P S Parfrey
Journal:  Kidney Int       Date:  1995-03       Impact factor: 10.612

7.  Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease.

Authors:  Kevin Damman; Vincent M van Deursen; Gerjan Navis; Adriaan A Voors; Dirk J van Veldhuisen; Hans L Hillege
Journal:  J Am Coll Cardiol       Date:  2009-02-17       Impact factor: 24.094

Review 8.  Role of vaptans in the management of hyponatremia.

Authors:  Ruediger W Lehrich; David I Ortiz-Melo; Mehul B Patel; Arthur Greenberg
Journal:  Am J Kidney Dis       Date:  2013-05-29       Impact factor: 8.860

9.  Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease.

Authors:  William M McClellan; Robert D Langston; Rodney Presley
Journal:  J Am Soc Nephrol       Date:  2004-07       Impact factor: 10.121

10.  Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†.

Authors:  Piotr Ponikowski; Dirk J van Veldhuisen; Josep Comin-Colet; Georg Ertl; Michel Komajda; Viacheslav Mareev; Theresa McDonagh; Alexander Parkhomenko; Luigi Tavazzi; Victoria Levesque; Claudio Mori; Bernard Roubert; Gerasimos Filippatos; Frank Ruschitzka; Stefan D Anker
Journal:  Eur Heart J       Date:  2014-08-31       Impact factor: 29.983

View more
  129 in total

1.  Risk Factors for Recurrent Acute Kidney Injury in a Large Population-Based Cohort.

Authors:  Kathleen D Liu; Jingrong Yang; Thida C Tan; David V Glidden; Sijie Zheng; Leonid Pravoverov; Chi-Yuan Hsu; Alan S Go
Journal:  Am J Kidney Dis       Date:  2018-10-25       Impact factor: 8.860

Review 2.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

Review 3.  Mitochondrial energetics in the kidney.

Authors:  Pallavi Bhargava; Rick G Schnellmann
Journal:  Nat Rev Nephrol       Date:  2017-08-14       Impact factor: 28.314

4.  What's new in cardiorenal syndrome?

Authors:  Michael Darmon; Miet Schetz
Journal:  Intensive Care Med       Date:  2018-04-26       Impact factor: 17.440

5.  Histamine provides an original vista on cardiorenal syndrome.

Authors:  Pierre-Louis Tharaux
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

6.  IL-35 Pretreatment Alleviates Lipopolysaccharide-Induced Acute Kidney Injury in Mice by Inhibiting NF-κB Activation.

Authors:  Linkun Hu; Cheng Chen; Jun Zhang; Kerong Wu; Xuefeng Zhang; Haiyan Liu; Jianquan Hou
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

7.  The midrange left ventricular ejection fraction (LVEF) is associated with higher all-cause mortality during the 1-year follow-up compared to preserved LVEF among real-world patients with acute heart failure: a single-center propensity score-matched analysis.

Authors:  Josip Anđelo Borovac; Katarina Novak; Josko Bozic; Duska Glavas
Journal:  Heart Vessels       Date:  2018-08-29       Impact factor: 2.037

8.  Incident Hospitalization with Major Cardiovascular Diseases and Subsequent Risk of ESKD: Implications for Cardiorenal Syndrome.

Authors:  Junichi Ishigami; Logan T Cowan; Ryan T Demmer; Morgan E Grams; Pamela L Lutsey; Juan-Jesus Carrero; Josef Coresh; Kunihiro Matsushita
Journal:  J Am Soc Nephrol       Date:  2020-01-09       Impact factor: 10.121

9.  The Loss of GSTM1 Associates with Kidney Failure and Heart Failure.

Authors:  Adrienne Tin; Robert Scharpf; Michelle M Estrella; Bing Yu; Megan L Grove; Patricia P Chang; Kunihiro Matsushita; Anna Köttgen; Dan E Arking; Eric Boerwinkle; Thu H Le; Josef Coresh; Morgan E Grams
Journal:  J Am Soc Nephrol       Date:  2017-07-18       Impact factor: 10.121

10.  Clinical significance of sFRP5, RBP-4 and NT-proBNP in patients with chronic heart failure.

Authors:  Yu An; Qingsong Wang; Hong Wang; Na Zhang; Fengming Zhang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.